Difference between revisions of "Dactinomycin (Cosmegen)"

Revision as of 16:17, 4 June 2022

General information

Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

12/10/1964: Initial FDA approval
3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of Wilms tumor, childhood rhabdomyosarcoma, Ewing sarcoma and metastatic, nonseminomatous testicular cancer. (Based on NWTS-1, NWTS-2, NWTS-3)
3/13/2009: (earliest label available on Drugs@FDA) Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
3/13/2009: (earliest label available on Drugs@FDA) Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Also known as

Generic names: AC-DE, actinomycin D
Brand names: Cosmegen, Dacmozen, Lyovac

References

[insert-1] 1.0 ^1.1 Dactinomycin (Cosmegen) package insert

[2] Dactinomycin (Cosmegen) package insert (locally hosted backup)

[3] Dactinomycin (Cosmegen) patient drug information (Chemocare)

[4] Dactinomycin (Cosmegen) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 23: / Line 23: @@
 ==History of changes in FDA indication==
 * 12/10/1964: Initial FDA approval
-* 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Wilms tumor]], childhood [[rhabdomyosarcoma]], [[Ewing sarcoma]] and metastatic, nonseminomatous [[testicular cancer]].
+* 3/13/2009: (earliest label available on Drugs@FDA) Approved as part of a combination chemotherapy and/or multi-modality treatment regimen for the treatment of [[Wilms tumor]], childhood [[rhabdomyosarcoma]], [[Ewing sarcoma]] and metastatic, nonseminomatous [[testicular cancer]]. ''(Based on NWTS-1, NWTS-2, NWTS-3)''
 * 3/13/2009: (earliest label available on Drugs@FDA) Approved as a single agent, or as part of a combination chemotherapy regimen, for the treatment of [[gestational trophoblastic neoplasia]].
 * 3/13/2009: (earliest label available on Drugs@FDA) Approved as a component of regional perfusion for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.